Prolonged survival following everolimus combined with temozolomide for metastatic malignant melanoma with FBXW7 mutation: a case report and literature review.

Abstract excerpt

Metastatic unresectable malignant melanoma (MM) owing to its intrinsic biological invasion potential and low sensitivity to radiochemotherapy has a poor prognosis and a high rate of mortality; the mean survival period is only 6-8 months, and the 5-year survival rate is less than 10%. The progression of patients with brain and liver metastases is worse than those with other distant or visceral metastases. With the...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Brain Neoplasms
• Share to Dacarbazine